Articles producció científicaMedicina i Cirurgia

Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

  • Datos identificativos

    Identificador:  imarina:9162447
    Autores:  Watts, Gerald F; Catapano, Alberico L; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale
    Resumen:
    The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Otros:

    Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S1567568821000088?via%3Dihub
    Referencia de l'ítem segons les normes APA: Watts, Gerald F; Catapano, Alberico L; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale (2020). Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atherosclerosis Supplements, 42(), E30-E34. DOI: 10.1016/j.atherosclerosissup.2021.01.006
    Referencia al articulo segun fuente origial: Atherosclerosis Supplements. 42 E30-E34
    DOI del artículo: 10.1016/j.atherosclerosissup.2021.01.006
    Año de publicación de la revista: 2020
    Entidad: Universitat Rovira i Virgili
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Fecha de alta del registro: 2025-02-18
    Autor/es de la URV: Masana Marín, Luis
    Departamento: Medicina i Cirurgia
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Tipo de publicación: Journal Publications
    Autor según el artículo: Watts, Gerald F; Catapano, Alberico L; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Áreas temáticas: Peripheral vascular disease, Medicine (miscellaneous), Medicina iii, Medicina i, Internal medicine, Farmacia, Ciências biológicas iii, Cardiology and cardiovascular medicine, Biotecnología
    Direcció de correo del autor: luis.masana@urv.cat
  • Palabras clave:

    Medication adherence
    Hypolipidemic agents
    Hypercholesterolemia
    Hydroxymethylglutaryl-coa reductase inhibitors
    Humans
    High risk patients
    Heart disease risk factors
    Cardiovascular diseases
    Cardiovascular disease
    Cardiology and Cardiovascular Medicine
    Internal Medicine
    Medicine (Miscellaneous)
    Peripheral Vascular Disease
    Medicina iii
    Medicina i
    Farmacia
    Ciências biológicas iii
    Biotecnología
  • Documentos:

  • Cerca a google

    Search to google scholar